An Ex Vivo Perfusion System Emulating In Vivo Conditions in Noncirrhotic and Cirrhotic Human Liver
Thomas Schreiter(Universitätsklinikum Knappschaftskrankenhaus Bochum), Ali Canbay(Universitätsklinikum Knappschaftskrankenhaus Bochum), Jan‐Peter Sowa(Universitätsklinikum Knappschaftskrankenhaus Bochum), Guido Gerken, G. Marquitan(University of Louisville), Martina Bröcker‐Preuß(University of Louisville), Hideo A. Baba(Essen University Hospital), Gavin E. Arteel(University of Pittsburgh), Marcus Furch(University of Louisville), Robert K. Gieseler, Malin Darnell(AstraZeneca (Sweden)), Zoltán Máthé(Semmelweis University), Tommy B. Andersson(Karolinska University Hospital), Jürgen Treckmann(Essen University Hospital)
Cited by 8
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
|Journal of Clinical Investigation|2004|620
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
|Journal of Clinical Investigation|2004|598
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
|International Journal of Cancer|2010|520